FARMAKOVİJİLANS DERNEĞİ

[ Arşiv ]

Değerli Üyelerimiz,

Sten Olsson'un vefatını öğrenmiş olmaktan çok üzgünüz. Sten ömrünü İlaç güvenliği uğrunda harcamış, hem alanda hem de herkesin yüreğinde derin izler bırakmış bir şahsiyetti.
Ailesine, arkadaşlarına ve tüm Farmakovijilans camiasına başsağlığı diliyoruz.

Farmakovijilans Derneği Yönetim Kurulu

We are very sad to be informed that Sten Olsson passed away. Sten had spent all his life for Drug Safety and left deep remarks on the field and on everybody's heart.

Our deepest condolences to his family, friends and to pharmacovigilance society.

10 Kasım'da Atamızı rahmet ve özlemle anıyoruz.

Türk İlaç Kurumunda görev değişimi: Sayın Dr Hakkı Gürsöz'e kuruma değerli katkıları için teşekkür eder, Yeni Kurum Başkanımız Sayın Dr. Ecz. Harun Kızılay'a yeni görevinde başarılar dileriz.

Uluslararası Farmakovijilans Derneği (ISOP) tarafından yayınlanan COVID-19 pandemisinde güvenli ilaç kullanımı ile ilgili bilgilendirme broşürünü siz değerli üyelerimizle paylaşıyoruz.

Covid Pandemi Döneminde Advers etki bildirimlerini TİTCK TÜFAM oluşturduğu özel formlar ile takip etmektedir.

The list of individual drugs that cause kidney damage is so long that it’s hard to collect all of them

Ten drugs or drug classes treating everything from obesity to arthritis made the latest watch list of drugs with possible safety issues that was released by the US Food and Drug Administration (FDA) last week.

Please feel free to forward this announcement to your colleagues as broadly as you can.

A controversial clinical trial of the antidepressant Paxil came to the wrong conclusion when it declared the drug safe and effective for treating troubled teenagers, according to a reanalysis of the original data more than a decade later.

People with four or more ER visits in the past year were 48 times more likely to die of prescription drug overdose compared to those who visited an ER once or not at all, researchers found. With three visits a year, the risk of overdose death from a prescription drug was 17 times greater.

European Journal of Clinical Pharmacology
February 2015, Volume 71, Issue 2, pp 151-158
Date: 06 Dec 2014

The European Medicines Agency (EMA) has updated its procedural guidance to ensure that marketing-authorisation holders are prepared for the submission of periodic safety update reports (PSURs) for nationally authorised medicines subject to European Union (EU) single assessment.

TITCK Ek izlemeye tabi ilaçlar listesi yayımladı.

ALLAS, TX — Contrary to a lot of observational data and common belief even among clinicians, regular intake of naproxen entails more cardiovascular risk than ibuprofen, according to an analysis of nonsteroidal...

The US Food and Drug Administration (FDA) has launched a long-awaited technology initiative intended to free regulatory data that was once difficult to obtain and harder still to make sense of.

The European Medicines Agency has updated its guidance for pharmaceutical companies on biosimilar medicines to reflect the European Commission's confirmation....

There has been a lot of discussion regarding the off-label use of drugs.  This has been a focus of interest for FDA, EMA, MHRA and other health agencies around the world

Michael O'Riordan

• Terminoloji
• Tanımlar
• Advers Etki / Toksik Etki Benzerlik ve Farklılıklar
• Sinyal Üretimi

« Geri